Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

VSTM $1.57 0.1400 +9.79%
KPTI $9.43 0.7300 +8.39%
OMED $13.80 0.9000 +6.98%
CYTR $2.78 0.1800 +6.92%
RXDX $6.90 0.4300 +6.65%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VRML $1.15 -0.1000 -8.00%
CTIX $1.59 -0.0700 -4.22%
CPXX $17.11 -0.7100 -3.98%
LXRX $12.93 -0.4400 -3.29%
FBIO $2.69 -0.0800 -2.89%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Raising The Survival Bar, And Access To Information, On Metastatic Cancer

(Forbes) May 13, 2016 - The public has every right to current information, on what’s known about survival after a diagnosis of metastatic breast cancer, and for all forms of cancer.
read article 

Cancer Charities In Desperate Plea To Cameron Over Drugs Rationing Plan

(The Telegraph [UK]) May 15, 2016 - Leading cancer experts have pleaded with the Prime Minister to prevent NHS plans which they say could deny life-extending drugs to thousands of dying patients.
read article 

Roche Moves Court To Block Copies Of Cancer Drug Avastin, A La Herceptin

(The Economic Times [Mumbai, India]) May 16, 2016 - Swiss biotechnology giant Roche has sued the Drug Controller General of India in Delhi High Court along with Hyderabad-based Hetero Drugs over the process followed for approval of copies of complex biotech drugs or biosimilars of Avastin (bevacizumab), its blockbuster brand that is used to treat at least six forms of advanced cancers.
read article 

Counterfeit Version of BiCNU Discovered in Some Foreign Countries

(ASCO in Action) May 16, 2016 - On May 13, the Food and Drug Administration (FDA) posted information on its website informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries.
read article 

Untreated Sleep Apnea May Be Related to Melanoma Aggressiveness

(ATS 2016) May 16, 2016 - Untreated severe obstructive sleep apnea (OSA) is associated with increased aggressiveness of malignant cutaneous melanoma, according to the first multicenter prospective study on the relationship between sleep-disordered breathing (apnea or hypopnea) and cancer.
read press release 

NeOnc Technologies Announces Initiation of Phase 1/2a Clinical Trial of NEO100™ in Recurrent Glioblastoma Multiforme (GBM)

(4-traders) May 14, 2016 - NeOnc Technologies, Inc., a privately held biotechnology company today announced the initiation of its multi-center Phase 1/2a clinical trial of NEO100 with the first patient being treated at the Cleveland Clinic.
read article 

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

(Yahoo! Finance) May 13, 2016 - Hutchison China MediTech Limited today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or metastatic colorectal cancer in China, where an estimated 390,000 new cases of CRC were diagnosed in 2012.
read article 

New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer

(Merck) May 16, 2016 - Data at ASCO evaluates KEYTRUDA as single agent and in novel combinations in more than 15 different cancers, including several new tumors.
read corporate press release 

Genetic Biomarker May Predict Nerve Pain Side Effects Associated With Prostate Cancer Treatment

(Moffitt Cancer Center) May 12, 2016 - New study finds genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients.
read press release 

Increased Physical Activity Associated with Lower Risk of 13 Types of Cancer

(NCI) May 16, 2016 - A new study of the relationship between physical activity and cancer has shown that greater levels of leisure-time physical activity were associated with a lower risk of developing 13 different types of cancer.
read press release 

Man Receives First Penis Transplant in the United States

(New York Times) May 16, 2016 - A man whose penis was removed because of cancer has received the first penis transplant in the United States, at Massachusetts General Hospital in Boston.
read article 

Lenvatinib in Combination with Everolimus

( May 16, 2016 - On May 13, 2016, the U. S. Food and Drug Administration approved lenvatinib capsules (Lenvima, Eisai, Inc.), in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.
read article 

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

(TheStreet) May 16, 2016 - A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday.
read article 

FDA Approves Eisai's LENVIMA (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

(Eisai) May 13, 2016 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA®(lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy.
read corporate press release 

Cancer Patient Receives First Penis Transplant in US

(ABC News/Associated Press) May 16, 2016 - A cancer patient has received the first penis transplant in the United States, a Boston hospital said Monday.
read article 

American Cancer Society Report Assesses Progress against Goals Set for Nation

(ACS) May 13, 2016 - A new report assesses how the nation fared against the ambitious challenge goal set by the American Cancer Society to reduce the cancer death rates by 50% over 25 years ending in 2015.
read press release 

Hospitals, Insurers Drop on Ruling Against Obamacare Funding

(Bloomberg) May 12, 2016 - Hospital and insurer stocks dropped after a federal judge in Washington ruled that some of the funding for President Barack Obama’s signature health-care law is unconstitutional, potentially jeopardizing a source of their revenue.
read article 

Regeneron CEO Says Drug Price Critique by Independent Group Unscientific

(Reuters) May 12, 2016 - Regeneron Pharmaceuticals Chief Executive Leonard Schleifer on Thursday took aim at an influential drug pricing watchdog, saying a critique of the company's new cholesterol lowering therapy was non-scientific.
read article 

Finding Value-Based Payment Measures That Work

(MedPage Today) May 12, 2016 - Physicians and other health policy experts explored the challenges of getting value-based payment right at a briefing hosted by Health Affairs on Thursday.
read article (free registration required) 

Experts Decry Tying Medical Research Funds to FDA Standards Changes

(Wall Street Journal) May 12, 2016 - Moves in Congress to link billions of dollars in new medical research funding to revised standards for drug and medical-device approvals are troubling some public-health experts, who say the combination makes it too easy for lawmakers to support lower patient-safety standards.
read article (paid subscription required) 

Leading Surgical Oncology Societies Call for Global Curriculum to Address Variations, Inadequacies in Training

(ECCO) May 12, 2016 - The lack of an adequately trained workforce of surgical oncologists can be a major detriment in efforts to address the rising global cancer burden, according to two leading international surgical oncology societies.
read press release 

Post-Mortem Cancer Study Goes National

(Cancer Research UK) May 13, 2016 - Cancer Research UK has today announced a £4 million investment to expand the UK's first ever national study collecting blood and tissue samples from patients who have died from cancer, in a bid to shed light on what happens during the final stages of the disease.
read press release 

AACR/AACI/ASCO to Honor U.S. Representatives Castor, Fleischmann as Part of Capitol Hill Day to Advocate for Cancer Research Funding During National Cancer Research Month

(AACR) May 11, 2016 - The American Association for Cancer Research (AACR), the Association of American Cancer Institutes (AACI), and the American Society of Clinical Oncology (ASCO) will honor U.S. Representatives Kathy Castor (D-Fla.) and Chuck Fleischmann (R-Tenn.) for their outstanding leadership on behalf of cancer research at a reception on May 11.
read press release 

Big Talk About Big Data, but Little Collaboration

(The Hill) May 13, 2016 - There's been much talk lately about big data's potential value in treating cancer, but little effort has been made to make big data bigger — and more effective — by sharing what's being collected.
read article 

Sanofi Presses On with Threat to Oust Medivation's Board

(Reuters) May 13, 2016 - France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a $9.3 billion acquisition offer.
read article